In Medicare, insulin is covered under Medicare Part D, a Medicare Advantage prescription drug (MAPD) plan, or, in some cases, Medicare Part B. Since 2023, the Inflation Reduction Act (IRA) has capped ...
The Medicare program effectively reduced insulin costs, improved adherence, and increased plan enrollment, benefiting both patients and the federal government. The initiative involved major insulin ...
KFF Biden era law improves Medicare Part D coverage for high-cost drugs ahead of 2026 price negotiations, enhancing patient access nationwide.
CMS’ Part D Senior Savings Model effectively increased insulin use while reducing out-of-pocket costs among Medicare beneficiaries, according to a RAND report published Sept. 22. The program also ...
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
GALWAY, Ireland, Feb. 2, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and ...
CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage of GLP-1 receptor agonists "very soon." (CNBC) Preclinical studies "have consistently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results